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A B S T R A C T
Objective: Mutations in the SLC26A4 gene cause both Pendred syndrome and autosomal recessive
nonsyndromic hearing loss (ARNSHL) at the DFNB4 locus. The SLC26A4 mutations vary among different
communities. Previous studies have shown that mutations in the SLC26A4 gene are responsible for the
more common syndromic hereditary hearing loss in Iran. This study assesses the possibility of a founder
mutation for Pendred syndrome in northwest Iran.
Materials and methods: In this study, we performed comprehensive clinical and genetic evaluations in
two unrelated families from northwest Iran with nine members affected by hearing loss (HL). After
testing short tandem repeat (STR) markers to conﬁrm linkage to the SLC26A4 locus, we screened the
SLC26A4 gene by Sanger sequencing of all 21 exons, exon–intron boundaries and the promoter region for
any causative mutation. We identiﬁed the same causative mutation in these two families as we had
detected earlier in two other Azeri families from northwest Iran. To investigate the possibility of a
founder effect in these four families, we conducted haplotype analysis, and 14 single nucleotide
polymorphisms (SNPs) throughout the SLC26A4 gene were genotyped.
Results: Patients in the two families showed the phenotype of Pendred syndrome. A known frameshift
mutation (c.965insA, p.N322Fs7X) in exon 8 was identiﬁed in the two families, which was the same
mutation that we detected previously in two other Azeri families. The results of haplotype analysis
showed that all 15 patients from four families shared the founder mutation. Common haplotypes were
not observed in noncarrier members.
Conclusions: Based on the results of our two studies, the c.965insA mutation has only been described in
Iranian families from northwest Iran, so there is evidence for a founder mutation originating in this part
of Iran.
 2014 Elsevier Ireland Ltd. All rights reserved.
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Hearing loss (HL) is a common sensorineural disorder affecting
one out of 500 live births [1]. HL is mainly prelingual and recent
studies suggest that more than 75% of cases of childhood HL have a
genetic origin, such as syndromic forms (25%) and non-syndromic
(NS) forms (75%) [1,2]. Mutations in the SLC26A4 gene have been
associated with Pendred syndrome (PS, MIM # 274600) and with
DFNB4 non-syndromic hearing loss (NSHL, MIM # 600791).
Pendred syndrome (PS) is an autosomal recessive disorder that
is associated with sensorineural deafness, congenital and severe to
profound temporal bone abnormalities, goiter and iodide organi-
ﬁcation defects resulting in a positive perchlorate discharge test
from the goiter usually in late childhood to early adulthood. In the
absence of thyroid dysfunction, patients are considered to be form
NSHL DFNB4 [3,4].
The SLC26A4 gene (NM_000441) encodes pendrin, an iodide–
chloride transporter responsible for both NSHL (DFNB4) and PS.
Pendrin is expressed in the kidneys, inner ear, and thyroid. In the
thyroid, pendrin probably transports iodide ions out of cells and
into the inner ear; it is responsible for establishing an appropriate
balance between charged particles such as chloride and bicarbon-
ate ions [5]. Mutations in the SLC26A4 gene probably affect pendrin
activity, causing an imbalance of ions and ﬂuid levels in the inner
ear. These changes may impair the structure of the inner ear, thus
affecting hearing [6]. The SLC26A4 gene is located on chromosome
7q22.3–7q31.1 and consists of 21 exons [7].
So far, more than 280 mutations in the SLC26A4 gene have been
identiﬁed in patients with PS and DFNB4 [8,9]. Many of these
mutations are common in most people, but some have only been
Fig. 1. Map of Iran including the locations of the four Azeri families; two families
(C, D) from Ardabil and Uremia Provinces, respectively, were the subject of this
study, and two families (A, B) from Ardabil Province located in northwestern Iran,
participated in our present and previous studies (shown with yellow points).
(For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)reported in one ethnic group, for example, the c.965insA mutation
has only been reported in the Iranian population [10]. In some
ethnic populations where a speciﬁc mutation is common, mutant
alleles may share ancestry (founder mutations) [11–13].
In our study, we report four unrelated Azeri families from
northwest Iran with PS, all of whom have an adenine insertion
c.965insA at exon 8. From SNP haplotype analysis of mutant alleles
in these patients, the c.965insA mutation was determined to be a
founder mutation.
2. Materials and methods
2.1. Samples
Four unrelated Azeri families from northwest Iran (Fig. 1) with
the syndromic form suggestive of Pendred syndrome were
included in this study. Two of the families (Families C and D),
including nine individuals with hearing impairment (six males and
three females, age range 7–24 years), were referred to our center
for molecular diagnosis and the other two families (Families A and
B) were from our previous study [10]. Before this study, all
participants provided written informed consent according to the
protocol approved by the ethics committee of the University of
Social Welfare and Rehabilitation Sciences. We performed a
comprehensive clinical investigation including functional thyroid
tests, the perchlorate discharge test, and serum-free thyroxine and
thyrotropin tests to reach a ﬁrm diagnosis of PS. Computed
tomography (CT) scans of the temporal bone were also performed
to check for vestibular aqueduct enlargement.
The perchlorate discharge test involved the oral administration
of iodine-131, and the uptake of radioiodide in the thyroid was
measured 2 h later. Potassium perchlorate was given orally before
the test. The test was considered to be positive when, 1 h after the
perchlorate had been administered, the radioiodide in the thyroid
had decreased by more than 10% compared to the initial uptake.Peripheral venous blood samples were obtained for analysis of
genomic DNA, and genetic evaluations were performed on all patients
affected by Pendred syndrome. Each family had at least two affected
children, all of whom had severe to profound hearing impairment
(90–120 dB), and were negative for GJB2 and GJB6 mutations.
2.2. Mutation detection
We used four short tandem repeat (STR) markers (D7S496,
D7S523, D7S501 and D7S1817) for homozygosity mapping
analysis. After the STR markers had conﬁrmed the linkage to the
SLC26A4 locus, all exons, exon–intron boundaries, and the
promoter region of the SLC26A4 gene were ampliﬁed by polymer-
ase chain reaction (PCR) (primer sequences and PCR conditions
available upon request) and sequenced in an ABI 3130-Avant DNA
analyzer (Applied Biosystems, Foster City, CA, USA).
2.3. Haplotype analysis method
For haplotype analysis, 14 highly polymorphic single nucleotide
polymorphism (SNP) markers, at 12 centimorgan intervals
surrounding the c.965insA mutation (Chr. 7: 105471384–
105471384 to Chr. 7: 116969876–116969876) closely linked to
SLC26A4, were genotyped (R1–R14) (Fig. 2C). Oligonucleotide
primer sequences were obtained from the National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov). The
ampliﬁed PCR products were sequenced directly using an ABI
3130-Avant DNA analyzer (Applied Biosystems). Codon Usage
Analyzer software was used to analyze the sequence data.
3. Results
Follow-up studies focused on four large families. Two of them
(Families C and D) were included in this study and two others
(Families A and B) had already been studied and reported in 2009
Fig. 2. (A) Genomic organization of the SLC26A4 gene located on chr.7, around the c.965insA mutation and 14 SNP variations that we selected for haplotype analysis. (B) The
block from R6 to R11 that was shared between our four families. (C) The names of the 14 selected SNPs.
Fig. 3. Sequence electropherogram of the insertion Adenine (c.965insA) in exon 8 (p.N322Fs7X). SLC26A4 gene is shown in the upper panel (the black box in sequencing
analysis data illustrates insertion A).
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with Pendred syndrome among 27 siblings from two provinces,
Ardabil (Families A, B and C) and Uremia (Family D). In this study,
we describe how homozygosity mapping has led to the identiﬁca-
tion of a frameshift mutation in the SLC26A4 gene in all of these
families.
3.1. Haplotype analysis
Molecular analysis revealed a known frameshift mutation
(c.965insA, p.N322fs7X) in exon 8 which led to a stop codon in the
SLC26A4 gene in all four families (15 patients) (Fig. 3). Eight
patients in three families (Families A, C and D) were homozygous
for this mutation and three patients in one family (Family B) wereTable 1
List of families with their origins, variations and genotype–phenotype correlation.
Family Origin Description Variation 
Family A Ardabil Previous study [10] c.965insA
Family B Ardabil Previous study [10] c.L597/c.9
Family C Ardabil Current study c.965insA
Family D Uremia Current study c.965insAcompound heterozygous for the c.L597S/c.965insA mutation
(Table 1) [10].
Because the mutation c.965insA was found in at least one allele
in the affected individuals from northwest Iran, we compared the
haplotypes of the father, mother, one normal and two affected
individuals from each family by genotyping 14 SNP markers at a
distance of around 12 centimorgans in the SLC26A4 gene region. In
the four families, c.965insA was associated with a common
haplotype for six SNP markers within and close to the putative
sulphate transporter gene (PDS) (rs2712218, rs2248465,
rs12705437, rs940770, rs2396753 and rs69447607). The four
families (A, B, C and D) had the c.965insA mutation, and a common
haplotype was only seen in c.965insA carriers, indicating a founder
effect for this mutation (Fig. 4).Genotype Phenotype
/c.965insA Homozygous Pendred syndrome
65insA Compound heterozygote Pendred syndrome
/c.965insA Homozygous Pendred syndrome
/c.965insA Homozygous Pendred syndrome
Fig. 4. Genotype and haplotype data for the four families. Each of the four boxes shows: top: family pedigree; left: genotypes; bottom: haplotypes of ﬁve individuals in each
family (F: father, M: mother, N: normal, and A: two affected). Carriers of c.965insA share a common haplotype (blue color) not observed in noncarrier members, suggesting a
founder effect. In Family B, the c.L597S mutation was found in the father and two paternal siblings. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)
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The four families all showed the syndromic phenotype of
Pendred syndrome. The pedigree of the families is shown in Fig. 3.
All patients had prelingual severe hearing impairment conﬁrmed
by audiometric evaluation. The thyroid function test showed
thyroid status with diffuse goiter, and temporal bone scans
revealed vestibular aqueduct enlargement in three families.
Family A: All three affected females in this family had severe
hearing loss (age range 22–28 years). Goiter started after puberty
in all affected individuals. They all had hypothyroidism, which was
controlled by medication.
Family B: This family had three affected individuals aged
between 28 and 34 years. They had moderate to severe hearing
impairment and diffuse goiter which had started about 15 years of
age in all of them. The thyroid function test in the three affected
individuals showed a euthyroid state. Temporal bone scans in one
patient showed massive vestibular aqueduct enlargement (class 6).
Family C: In this family, there were seven affected individuals
aged between 7 and 24 years with severe prelingual hearing
impairment and goiter, which had started after puberty (between
13 and 24 years) in four patients. Temporal bone scans in two
patients (one boy and one girl) showed vestibular aqueduct
enlargement class 6 (class 1–6).
Family D: This family had two affected individuals aged 18 and
27 years both with profound congenital hearing loss. Their goiter
had started at age 14 and 16 years, respectively.
4. Discussion
Mutations in the SLC26A4 gene encoding for pendrin are
responsible for both syndromic and non-syndromic HL. Pendredsyndrome is an autosomal recessive disorder associated with
hearing loss, goiter and iodide organiﬁcation defect conﬁrmed by a
positive perchlorate discharge test [14].
Currently, more than 280 mutations have been identiﬁed in
the SLC26A4 gene in patients with PS and DFNB4 [8]. Many of
these mutations are common in most people, but some have
only been reported in one ethnic group. Speciﬁc mutations
identiﬁed repeatedly are called founder mutations. For exam-
ple, the c.965insA mutation had already been reported in two
families from west Iran [10–15], and, in the present study, we
found this mutation in two other Azeri families. Since the
identiﬁcation of founder mutations in different ethnic groups
and their geographical distribution has important implications
for the design of mutation screening programs, and mutation in
the SLC26A4 gene is the second most common cause of deafness
in the Iranian population [10], we therefore investigated the
possibility of a founder mutation in northwest Iran in the
current study.
From haplotype analyses, we identiﬁed the c.965insA
mutation in both mutant alleles in the two individuals affected
in Families A, C, and D (they were homozygous mutations)
and in one mutant allele in the two individuals affected in
Family B (the pathogenic mutation in this family was c.L597S/
c.965insA in a compound heterozygous form that was reported
earlier [10], and we found this mutation in just one mutant
allele in normal individuals and their parents in our four Azeri
families.
Our results support the founder mutation theory for the
c.965insA mutation. We suggest that, as the c.965insA mutation is
more frequent in northwest Iran, it should be included in mutation
screen programs in families with suspected syndromic hearing loss
indicative of Pendred syndrome.
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